APA (7th ed.) Citation

Chen, J. Y., Johnson, L., McKenna, K. M., Choi, T. S., Duan, J., Feng, D., . . . Weissman, I. L. (2022, June). P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS). HemaSphere.

Chicago Style (17th ed.) Citation

Chen, J. Y., et al. "P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS)." HemaSphere Jun. 2022.

MLA (9th ed.) Citation

Chen, J. Y., et al. "P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS)." HemaSphere, Jun. 2022.